Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc.
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute
Sotio Biotech Inc.
Mayo Clinic
Neonc Technologies, Inc.
Abramson Cancer Center at Penn Medicine
H. Lee Moffitt Cancer Center and Research Institute
Ariceum Therapeutics GmbH
ImmunityBio, Inc.
University of Southern California
University of Pittsburgh
Memorial Sloan Kettering Cancer Center
Transgene
TuHURA Biosciences, Inc.
Medicenna Therapeutics, Inc.
Merck Sharp & Dohme LLC
Weill Medical College of Cornell University
Fred Hutchinson Cancer Center
Vincerx Pharma, Inc.
University of Florida
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
National Cancer Institute (NCI)
Fate Therapeutics
Exicure, Inc.
Stanford University
Incyte Corporation
MultiVir, Inc.